Compare ITRG & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITRG | ADCT |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.5M | 454.5M |
| IPO Year | N/A | 2020 |
| Metric | ITRG | ADCT |
|---|---|---|
| Price | $3.50 | $4.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $4.00 | ★ $7.60 |
| AVG Volume (30 Days) | ★ 2.2M | 743.6K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $219,125,000.00 | $75,209,000.00 |
| Revenue This Year | $709.65 | $11.78 |
| Revenue Next Year | $36.86 | $4.83 |
| P/E Ratio | $45.52 | ★ N/A |
| Revenue Growth | N/A | ★ 6.35 |
| 52 Week Low | $0.79 | $1.05 |
| 52 Week High | $3.52 | $4.80 |
| Indicator | ITRG | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 66.21 | 56.64 |
| Support Level | $2.73 | $3.95 |
| Resistance Level | $3.12 | $4.45 |
| Average True Range (ATR) | 0.23 | 0.26 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 96.83 | 76.72 |
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).